A low-grade squamous intraepithelial lesion, or LSIL, is a mildly abnormal change in the thin, flat cells lining the cervix, almost always caused by infection with human papillomavirus (HPV). The good news most people want to hear first: the vast majority of LSILs clear on their own without treatment. In one well-known study of young women, about 91% of LSILs had regressed within three years.1The Lancet. Natural history of low-grade squamous intraepithelial lesions in young women But the term still rattles people when it shows up on a Pap result, and understanding what it means, what drives it, and when it does warrant closer attention can save a lot of unnecessary worry.
What the Term Actually Describes
LSIL is a reporting category created by the Bethesda System, a standardized way of communicating Pap smear findings between labs and clinicians.2PubMed Central. The Bethesda System for reporting cervical cytology When a pathologist looks at your cervical cells under a microscope and sees certain changes in cell size, shape, and nuclear features that are consistent with HPV infection but remain mild and confined to the lower portion of the cell lining, the result is classified as LSIL. It corresponds roughly to what older terminology called CIN 1, or cervical intraepithelial neoplasia grade 1.
The key distinction is between “low-grade” and “high-grade.” Low-grade means the cellular changes are superficial and reflect an active HPV infection rather than a pre-cancerous process that has taken hold deeper in the tissue. High-grade squamous intraepithelial lesions (HSIL), by contrast, involve more pronounced changes extending further into the tissue layers, and those carry a higher risk of eventually becoming cancer if left alone. LSIL sits squarely at the mild end of that spectrum.
Pathologists sometimes note a feature called koilocytosis in LSIL samples, which refers to a distinctive hollowed-out look in infected cells. It is a classic visual hallmark of HPV’s effect on the cell, though its presence does not reliably predict whether the lesion will progress or regress.3PubMed Central. Koilocytosis in LSIL Cytology Has Limited Predictive Value for CIN2+ in HPV-Positive Women: Implications for Risk-Based Cytology Triage Distinguishing LSIL from benign look-alikes, such as inflammation-related changes in cells undergoing normal repair, requires careful attention to nuclear features and growth patterns.4PubMed Central. Cervical Pre-cancers: Biopsy and Immunohistochemistry
HPV and How LSIL Develops
Almost every case of LSIL traces back to HPV. In a study that followed young women over a median of five years, HPV infection was overwhelmingly the strongest risk factor for developing LSIL. Women with an HPV infection lasting one to two years had roughly ten times the risk of developing LSIL compared with uninfected women.5PubMed. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females Shorter infections still carried elevated risk, and even infections persisting beyond two years remained a significant driver. In practical terms, LSIL is the body’s visible reaction to the virus setting up shop in cervical cells.
There are more than a hundred HPV types, but the ones relevant here fall into two broad camps: low-risk types that cause warts and tend to be harmless, and high-risk (oncogenic) types that can, in a small minority of cases, eventually lead to cancer. LSIL can be caused by either camp, but the downstream implications depend heavily on which type is involved.
How Often LSIL Goes Away on Its Own
This is the single most reassuring piece of the puzzle. The body’s immune system clears the underlying HPV infection in most people, and when it does, the abnormal cells revert to normal. Research on young women found about a 61% probability of regression within the first 12 months, climbing to roughly 91% by three years.6The Lancet. Natural history of low-grade squamous intraepithelial lesions in young women Another study found that half of all LSILs regressed to normal or near-normal within just six months.7JNCI: Journal of the National Cancer Institute. Human Papillomavirus Infection and Time to Progression and Regression of Cervical Intraepithelial Neoplasia
Regression does not happen at the same pace for everyone, though. Women infected with oncogenic HPV types took longer to clear their lesions. The average time for LSIL regression in women with oncogenic HPV was about 14 months, compared with roughly 8 months for women with non-oncogenic types or no detectable HPV.8JNCI: Journal of the National Cancer Institute. Human Papillomavirus Infection and Time to Progression and Regression of Cervical Intraepithelial Neoplasia So the type of HPV affects both how quickly a lesion might disappear and how closely it should be watched.
When LSIL Does Progress
A minority of LSILs move in the wrong direction. In one study, about 9% of LSILs progressed to high-grade lesions, and the cases that did progress were overwhelmingly associated with HPV 16, the single most dangerous high-risk type. Progression was not found in patients infected only with low-risk types like HPV 6 and 11.9PubMed Central. Progression Low Squamous Intraepithelial Lesion and Human Papillomavirus Infections The story gets more nuanced when you look at the full range of high-risk types beyond HPV 16 and 18. One study found that infection with non-16/18 high-risk HPV types was actually a strong predictor of persistence and progression, and that testing solely for HPV 16 and 18 would miss the majority of patients whose LSIL went on to become high-grade.10PubMed. Non-16/18 high-risk HPV infection predicts disease persistence and progression in women with an initial interpretation of LSIL
The practical takeaway is that broader HPV testing, not just genotyping for types 16 and 18, gives a better picture of who needs closer surveillance. The virus type matters, but the assumption that only HPV 16 is dangerous oversimplifies what happens in the real world.
How Clinicians Manage an LSIL Result
Because most LSILs resolve without intervention, the standard approach is watchful waiting rather than immediate treatment. What “watchful waiting” looks like depends partly on your age and circumstances.
For younger patients, guidelines have historically recommended repeat Pap testing at 12-month intervals for up to two years before considering a colposcopy referral, reflecting the especially high regression rates in this age group.11PubMed Central. Management of adolescents who have abnormal cytology and histology The rationale is straightforward: sending every young person with an LSIL for an invasive procedure would create anxiety and cost without benefit for the vast majority whose lesions will vanish.
For adults aged 25 and older, the path often involves colposcopy, a close-up examination of the cervix using magnification, combined with HPV testing. The decision about whether and when to do colposcopy remains a matter of ongoing clinical discussion, particularly for borderline or low-grade findings.12PubMed Central. Role of colposcopy in the management of women with abnormal cytology Current U.S. guidelines use a risk-based framework that factors in your HPV status, your age, and your screening history to estimate how likely a high-grade lesion is lurking beneath the low-grade cytology.
Treatment at this stage, when it happens, is typically reserved for cases where a biopsy taken during colposcopy reveals a higher-grade lesion than the Pap result suggested. LSIL itself, confirmed on biopsy as CIN 1, is generally monitored rather than treated. Active treatment such as excision or ablation enters the picture only when the lesion persists for years or when biopsies show progression to CIN 2 or CIN 3.
Newer Triage Tools for Sorting Risk
One of the frustrations with LSIL management is that the label is broad. Some of those lesions genuinely harbor early high-grade changes that the Pap missed, while most are harmless. Researchers have been developing biomarker tests to better separate the two groups before resorting to colposcopy.
A dual-staining test that detects two proteins, p16 and Ki-67, in the same cell has shown particular promise. The idea is that when both proteins show up together, it signals that the cell cycle has been disrupted in a way more consistent with a progressing lesion than a transient infection. In a large multicenter study, this dual stain picked up about 88% of high-grade lesions among women with borderline or low-grade Pap results, while keeping specificity around 66%.13PubMed Central. Evaluation of p16/Ki-67 dual staining in detection of cervical precancer and cancers: a multicenter study in China Combining this dual stain with HPV DNA testing improved accuracy further. In one prospective study, women who tested negative for both HPV DNA and the dual stain had just a 1.2% risk of harboring a high-grade lesion, while those positive for both had a 27% risk.14PubMed. Triage of LSIL/ASC-US with p16/Ki-67 dual staining and human papillomavirus testing: a 2-year prospective study
HPV genotyping alone also carries useful information. Among women with LSIL cytology, HPV genotyping detected about 94% of underlying high-grade lesions, though at the cost of lower specificity, meaning it flagged many women who turned out to be fine.15PubMed. HPV genotyping and p16÷Ki-67 dual staining in the detection of high-grade cervical lesion in patients with LSIL on Pap smear These tools are increasingly being woven into clinical algorithms to help clinicians decide who really needs a colposcopy and who can safely wait.
LSIL in People Living with HIV
The immune system’s ability to clear HPV is central to LSIL regression, so anything that weakens immune function changes the equation. People living with HIV face a substantially higher incidence of LSIL, with a pooled risk roughly 3.7 times that of HIV-negative individuals, driven largely by increased HPV persistence.16AIDS. HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer
Importantly, LSIL in this population behaves differently. While the rate of progression to high-grade lesions was not dramatically different between HIV-positive and HIV-negative women in one study, persistence was far more common: about 64% of LSILs persisted in HIV-positive women compared with 35% in HIV-negative women. Antiretroviral therapy made a meaningful difference, lowering the risk of progression and improving clearance rates.17Journal of lower genital tract disease. Progression and persistence of low-grade cervical squamous intraepithelial lesions in women living with human immunodeficiency virus This finding underscores that HIV treatment is itself a form of cervical cancer prevention. For immunocompromised individuals more broadly, including organ transplant recipients on immunosuppressive drugs, closer surveillance intervals are generally recommended.
LSIL Beyond the Cervix
HPV does not confine itself to the cervix, and neither does LSIL. The same grading terminology applies to other sites where squamous cells line the surface.
Anal LSIL has become a growing concern, particularly among men who have sex with men and people living with HIV. The disease follows a similar HPV-driven pathway, and its incidence has been rising.18PubMed Central. Management of anal squamous intraepithelial lesions Anal LSIL progresses to high-grade lesions more frequently than cervical LSIL does in certain populations. In one study using high-resolution anoscopy, 41% of patients with anal LSIL had progressed to HSIL on follow-up biopsy within a median of 20 months. Patients who were positive for HPV 16 or 18 had the highest progression rates, reaching 67%, while those without high-risk HPV had a progression rate of only 7%.19The Journal of Infectious Diseases. Human Papillomavirus Genotypes Predict Progression of Anal Low-Grade Squamous Intraepithelial Lesions These numbers are strikingly higher than cervical LSIL progression rates, and they help explain the push toward anal cancer screening programs in high-risk groups.
Vulvar LSIL is another entity worth knowing about. It overlaps considerably with genital warts (condyloma), and the two are increasingly viewed as part of the same spectrum. Vulvar LSIL tends to appear flat and whitish, whereas condyloma more often appears raised, though the distinction is not always clear-cut.20Journal of Lower Genital Tract Disease. Vulvar Low-Grade Squamous Intraepithelial Lesion (LSIL) and Small Condyloma are Overlapping Clinicopathologic Entities A notable proportion of patients with vulvar or vaginal low-grade lesions also have concurrent or prior higher-grade disease elsewhere in the lower genital tract, which means discovery of vulvar LSIL sometimes prompts a broader look at the cervix and vagina too.21Modern Pathology. Low-Grade Vulvar and Vaginal Intraepithelial Neoplasia: Correlation of Histologic Features with Human Papillomavirus DNA Detection and MIB-1 Immunostaining
The Emotional Side of an Abnormal Pap
Getting the words “abnormal Pap smear” in a phone call or patient portal can trigger a wave of fear that is out of proportion to the actual medical risk. Research bears this out. One study measuring anxiety levels found that receiving an abnormal result caused a significant spike in anxiety scores, and while that anxiety decreased over time for most women, about 35% still had clinically meaningful anxiety 12 weeks later.22Psycho-Oncology. The psychosocial impact of an abnormal cervical smear result
A big part of the problem is terminology. “Lesion” sounds serious. “Intraepithelial neoplasia” sounds like cancer. Many people hear these words and assume the worst. In reality, LSIL is closer to a sign that your body is dealing with a common virus than it is to a cancer diagnosis. Clear communication from the clinician at the time of results, not just a form letter, matters enormously for managing this unnecessary distress.
How Vaccination Is Changing the Landscape
HPV vaccination, when given before exposure to the virus, prevents infection with the targeted types and thereby reduces the abnormal Pap results those infections would have caused. A population-level study found that vaccinated women had about a 24% lower rate of low-grade cervical abnormalities compared with unvaccinated women.23PubMed Central. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study That may sound modest, but low-grade abnormalities are extremely common, so a 24% reduction translates into a large number of women who are spared the anxiety, follow-up visits, and costs of managing an LSIL result.
The current vaccines cover HPV types 16 and 18, which cause the majority of cervical cancers, as well as several other oncogenic and low-risk types. Because LSIL can be caused by many HPV types beyond what vaccines cover, vaccination will not eliminate LSIL entirely. But in countries with high vaccine uptake, the downstream effects on screening volumes and healthcare costs are already measurable.
The Financial and Screening Burden
Even though most LSILs resolve without treatment, the cascade of follow-up testing they trigger is not free. In the United States, costs associated with an abnormal routine screening diagnosis ranged from about $300 for the mildest category to over $2,300 for high-grade findings, with confirmed CIN 1 (the biopsy equivalent of LSIL) averaging around $1,000 per case.24PubMed. The health care costs of cervical human papillomavirus–related disease Multiply that by millions of abnormal screening results annually, and the economic footprint is substantial. A nationwide study in China similarly concluded that the economic burden of squamous intraepithelial lesions is large, and that a significant portion of LSIL-related costs could be considered avoidable given the high spontaneous regression rate.25PubMed Central. Estimation of economic burden throughout course of cervical squamous intraepithelial lesion and cervical cancer in China: A nationwide multicenter cross-sectional study
This tension between catching the rare lesion that will progress and over-investigating the many that will not is at the heart of ongoing debates about screening intervals, triage strategies, and when to step in. Better risk-stratification tools, like the biomarker tests discussed earlier, could eventually shrink this burden by steering low-risk patients away from colposcopy and its associated costs, while keeping a close watch on the smaller group who genuinely needs it.
The Vaginal Microbiome Connection
An emerging area of research looks at whether the community of bacteria living in the vagina influences whether an HPV infection progresses or clears. The hypothesis is that certain microbial profiles create a local environment that either supports or undermines the immune response against HPV. Researchers are working to identify dominant microbial markers associated with high-grade versus low-grade lesions, with the goal of eventually using microbiome profiling to help predict which patients with LSIL are more likely to see their lesions regress and which might need closer follow-up.26PubMed Central. The interplay between the vaginal microbiome and innate immunity in the focus of predictive, preventive, and personalized medical approach to combat HPV-induced cervical cancer This work is still early-stage, but it represents a shift toward understanding LSIL not just as a virus-plus-cells story but as something shaped by the broader biological environment.
Screening Disparities Across the Globe
How LSIL is detected and managed varies dramatically by geography. In countries with long-established screening programs, low-grade abnormalities are caught early and routinely, often before any symptoms exist. In many African countries, cervical cancer screening remains limited, meaning that by the time lesions are detected, they may already be at a higher grade. This disparity in access helps explain regional differences in the prevalence of high-risk HPV among women with abnormal cytology and the higher rates of advanced cervical disease in settings where screening is sparse.27British Journal of Cancer / BMJ Global Health (Journal: BMJ Global Health). Worldwide burden of cervical human papillomavirus (HPV) in women over 50 years with abnormal cytology: a systematic review and meta-analysis LSIL is, in a sense, a luxury diagnosis: it means you had access to a screening test early enough to catch something that has a very good chance of going away on its own, which is exactly the kind of finding a well-functioning screening system is designed to produce.